Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,603 Cr
verified against source
Revenue YoY
14.6%
reported change
EBITDA
₹517.4 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY). India branded generics grew ~10%, outperforming the IPM by 100-150 bps, while international sales surged 25.4% YoY. The successful day-one launch of semaglutide in India captured an 11% unit market share in its first month. Management expects to sustain 100-150 bps outperformance in India and high single-digit US growth in FY27, though geopolitical headwinds may pressure margins. The key risk is rising input costs from global supply chain disruptions, which could limit margin expansion to the 20-21% range.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to sustain outperformance of 100-150 bps vs the Indian pharmaceutical market in FY27.
- US business expected to grow high single-digit YoY in dollar terms, with forex gains and new launches adding upside.
- Despite geopolitical headwinds, management expects EBITDA margin to be around 20-21% for FY27, similar to FY26.
- Company moving to new tax regime from April 2026, reducing effective tax rate to 27-29% from earlier 35-38%.
Risks flagged
- Rising logistics costs, API and packaging material prices due to geopolitical tensions could pressure margins.
- Base business in US faces value erosion; new launches may not fully offset if competition intensifies.
- Trade generic business grew only ~4% due to restructuring; recovery may be slower than expected.
- CEO Dr. Vikas Gupta is leaving; new CEO search is ongoing, which could cause temporary strategic drift.
Key quotes
- We crossed 3,000 crores. So it's been a fantastic year and I will let Vikas fill in more details.
- In the most recent IQVIA report, we could garner a market unit market share of around 11%.
- We have decided to move to the new tax regime from April 26 onwards. So the tax rate will be around 27 to 29% going forward.
Research modules